With a fixed injection protocol, iodixanol 320 mgI/mL yielded higher venous enhancement, whereas iodixanol 270 mgI/mL provided diagnostically acceptable portal/hepatic venous image quality on DECT with a lower iodine load. After adjustment, 320 mgI/mL was associated with higher odds of postcontrast acute kidney injury; this safety signal requires confirmation in larger iodine-matched studies.
Wang et al. (Fri,) studied this question.